Connect your AI

Biohaven BHVN Investment Purchases

Investment Purchases at other companies

Eli LillyLLY

$297M+50.8%

Rapport Therapeutics, Inc.RAPP

$30.37M-29.8%

Vir Biotechnology, Inc.VIR

$158.37M-8.8%

Protagonist TherapeuticsPTGX

$68.97M-67.8%

BridgeBio PharmaBBIO

$52.67M—

AnaptysBio, Inc.ANAB

$0-100%

Other financials

Income statement

Operating income-$130.4M+41.1%

Net income-$130.5M+41.1%

EPS (diluted)-$0.88+59.4%

Balance sheet

Cash & equivalents$277.1M+170%

Total debt$286.2M+706%

Total equity$129.5M-50.1%

Total assets$466.4M+1.6%

Cash flow

Operating cash flow-$149.9M+9.2%

CapEx--100%

Free cash flow-$149.9M+9.5%

Valuation

Market cap$2.23B-48.1%

Enterprise value$2.23B-46.3%

Returns & leverage

Return on equity-333%+17.9pp

Debt / equity2.2×+2.1×

Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's investment purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Biohaven's investment purchases?: Biohaven (BHVN) reported investment purchases of $19.79M in Q1 2026.
How has Biohaven's investment purchases changed year-over-year?: Biohaven's investment purchases decreased by 55.7% year-over-year, from $44.66M to $19.79M.
What does investment purchases mean?: Cash spent purchasing investment securities across all categories.